Table 1.
Demographic and clinical features of participants.
| Participant number, gender | Age rangeI | Diagnosis (at the time of surgery) | Psychiatric medication at time of surgery | Time since surgery (years) | Type of surgery | BMI at surgery (kg/m2) | BMI present time (kg/m2) | Greatest % total weight loss (any time post surgery) | % total weight loss (current time) | Change in BMI (kg/m2) | % Excess weight loss |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1F* | 30–40 | Schizo-affective disorder | Olanzapine Sodium valproate | 10 | Laparoscopic band (reversed) | 38.2* (est.) | 44.1* (est.) | 26.9 | -15.4 | −5.9* (est.) | −44.6%* (est.) |
| 2M | 60–70 | Bipolar disorder | Moclobemide Lamotrigine |
10 | Gastric bypass surgery | 42.0 | 30.7 | 31.5 | 26.8 | 11.2 | 66.2 |
| 3F | 60–70 | Bipolar disorder with psychotic features | Olanzapine Lithium Venlafaxine |
9 | Fobi pouch | 50.2 | 31.3 | 38.5 | 37.7 | 18.9 | 75.1 |
| 4F | 20–30 | Severe depression | Venlafaxine Mirtazapine Clonazepam |
2 | Fobi pouch | 44.3 | 31.9 | 40.6 | 28 | 12.4 | 64.2 |
| 5F | 50–60 | Severe depression with psychotic features | Quetiapine Clomipramine |
4 | Fobi pouch | 53.4 | 36.5 | 32.2 | 32.2 | 16.9 | 59.5 |
| 6F | 50–60 | Severe depression | Sodium valproate Amitriptyline |
8 | Fobi pouch | 70.6 | 39.0 | 50.6 | 44.8 | 31.7 | 69.4 |
| 7F | 50–60 | Bipolar disorder with psychotic features | Chlorpromazine Lithium Nortriptyline |
12 | Fobi pouch | 49.2 | 45.8 | 29.1 | 7.0 | 3.46 | 14.3 |
| 8F | 40–50 | Bipolar disorder with psychotic features | Quetiapine Lithium | 6 | Laparascopic band | 43.9 | 30.4 | 46.9 | 31 | 13.5 | 71.4 |
| 9M | 40–50 | Bipolar disorder | Lithium | 1 | Fobi pouch | 38.8 | 29.0 | 32.3 | 24 | 9.8 | 71.0 |
BMI, body mass index; est, estimated; F, female; kg, kilogram; m, meter; M, Male.
IExact ages not given to protect anonymity.
*Accurate BMI records not available for Participant 1. Weight available, height estimated at 165 cm, the average height of a New Zealand woman in order to provide BMI estimates.